Overview

Adoptive Cell Therapy Across Cancer Diagnoses

Status:
Active, not recruiting

Trial end date:
2020-09-30

Target enrollment:

Participant gender:

Summary

This study will perform tumor-infiltrating lymphocyte (TIL)-based adoptive T-cell therapy in combination with checkpoint inhibition on cancer patients across all cancer diagnoses.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Inge Marie Svane

Treatments:

Aldesleukin
Cyclophosphamide
Fludarabine phosphate
Ipilimumab
Nivolumab